What is the clinical evidence from this study?

Study design: Review. Population: Cardiac disease.

What question did this study set out to answer?

This research aims to explore how glucose and fatty acid transporters regulate energy production in the heart during disease.

April 30, 2008Cardiovascular ResearchOpen Access

Regulation of sarcolemmal glucose and fatty acid transporters in cardiac disease

View Full Paper

Ask AI

Bookmark

Key result

Permanent relocation of long-chain fatty acid transporters to the sarcolemma impairs insulin signaling and glucose utilization, contributing to cardiac dysfunction and heart failure.

Design

Review

Authors

RSRobert W. SchwenkDeutsches Diabetes-Zentrum e.V.JLJoost J.F.P. LuikenHeart Failure / Cardiomyopathy ABArend BonenUniversity of Guelph

Discussion

Member takes

Implication

May identify LCFA transporter relocation as a metabolic target in HF; leaves open whether modulating it restores function.

Key Points

This research aims to explore how glucose and fatty acid transporters regulate energy production in the heart during disease.
Examined the roles of GLUT1, GLUT4, CD36, and FABP(pm) in cardiac energy metabolism.
Investigated the trafficking mechanisms and signaling pathways of transporters at the sarcolemma.
Assessed the impacts of altered transporter localization on heart function and insulin signaling.
Elevated LCFA transporter levels, particularly CD36, correlated with impaired glucose utilization (P<0.05).
Reduced contractile function observed with permanent relocation of LCFA transporters to the sarcolemma.
Identification of distinct trafficking pathways for glucose vs. LCFA transporters, with potential therapeutic implications.

PICO

Population

Cardiac disease

Understanding the subcellular distribution and recycling of glucose and LCFA transporters may enable novel therapies to manipulate substrate preference and restore cardiac function in heart failure.

Cite This Study

Schwenk et al. (2008) conducted a review in Cardiac disease. Permanent relocation of long-chain fatty acid transporters to the sarcolemma impairs insulin signaling and glucose utilization, contributing to cardiac dysfunction and heart failure.

synapsesocial.com/papers/6a75cd3dd17bc701ee16225c https://doi.org/10.1093/cvr/cvn116

View Full Paper

Ask AI

Bookmark

Regulation of sarcolemmal glucose and fatty acid transporters in cardiac disease

Discussion

Member takes

Implication

Key Points

PICO

Cite This Study

Regulation of sarcolemmal glucose and fatty acid transporters in cardiac disease

Discussion

Member takes

Implication

Key Points

PICO

Cite This Study

Also Consider

Also Consider